Physician profile
Robert D Lynch
NPI 1841293198
$2,115.00
in general payments reported to CMS, 2019-2025
29 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $293 · 2021: $398 · 2022: $282 · 2023: $456 · 2024: $311 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $315.41 | 2021-2024 | Farxiga, Airsupra, Evusheld |
| Novo Nordisk INC | $242.14 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $228.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $191.19 | 2019-2025 | |
| Ethicon US, LLC | $165.99 | 2022-2023 | Dermabond Prineo, Stratafix, Vistaseal |
| Amarin Pharma, INC. | $150.43 | 2020-2021 | |
| Glaxosmithkline, LLC. | $102.97 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $77.30 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.98 | 2024-2025 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $57.44 | 2019-2020 | |
| Lilly USA, LLC | $54.16 | 2022-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $50.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.75 | 2021-2023 | |
| Lundbeck LLC | $41.57 | 2023 | Rexulti |
| Abbvie INC. | $41.06 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $37.90 | 2020-2021 | |
| Axsome Therapeutics, INC. | $29.86 | 2025 | Auvelity |
| Abbott Laboratories | $28.58 | 2022 | |
| Inspire Medical Systems, INC. | $24.13 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $23.41 | 2020 | |
| Paratek Pharmaceuticals, INC. | $23.16 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.28 | 2025 | |
| Daiichi Sankyo INC. | $19.09 | 2022 | |
| Merck Sharp & Dohme LLC | $17.72 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.70 | 2021 | |
| Millicent US INC | $15.17 | 2019 | |
| Seqirus USA INC | $13.51 | 2021 | |
| Vistapharm, INC. | $13.25 | 2021 | |
| Medtronic Vascular, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.